JW (Cayman) Therapeutics Co Ltd
HKEX:2126
JW (Cayman) Therapeutics Co Ltd
Net Income (Common)
JW (Cayman) Therapeutics Co Ltd
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
|
Net Income (Common)
-¥768m
|
CAGR 3-Years
23%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Net Income (Common)
-¥13.6B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Net Income (Common)
-¥1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Net Income (Common)
¥1.2B
|
CAGR 3-Years
23%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Net Income (Common)
¥8.5B
|
CAGR 3-Years
40%
|
CAGR 5-Years
47%
|
CAGR 10-Years
45%
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Net Income (Common)
¥1.3B
|
CAGR 3-Years
61%
|
CAGR 5-Years
73%
|
CAGR 10-Years
N/A
|
See Also
What is JW (Cayman) Therapeutics Co Ltd's Net Income (Common)?
Net Income (Common)
-768m
CNY
Based on the financial report for Dec 31, 2023, JW (Cayman) Therapeutics Co Ltd's Net Income (Common) amounts to -768m CNY.
What is JW (Cayman) Therapeutics Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-23%
Over the last year, the Net Income (Common) growth was 9%. The average annual Net Income (Common) growth rates for JW (Cayman) Therapeutics Co Ltd have been 23% over the past three years , -23% over the past five years .